Key clinical point: Pre-clinical data suggests maternal embryonic leucine zipper kinase (MELK) may be a novel drug target in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
Major finding: In cellular studies, the MELK inhibitor OTSSP167 demonstrated strong anti-cancer activity in several lymphoma cell lines.
Study details: A pre-clinical study examining the effects of MELK as a novel drug target in DLBCL and MCL.
Disclosures: The authors reported having no conflicts of interest.
Maes A et al. Blood Cancer J. 2019 Nov 18. doi: 10.1038/s41408-019-0249-x.